IMPDH2

Across TCGA pan-cancer cohorts, IMPDH2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IMPDH2 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IMPDH2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IMPDH2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where IMPDH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.286	0.795	.003	40	view →
CCRCC	DFS	Quartile	All	0.591	0.890	<.001	30	view →
GBM	OS	Median	All	0.255	0.527	.001	18	view →
LUAD	DFS	Median	II,III,IV	0.924	0.783	.016	13	view →
UCEC	OS	Tertile	All	0.811	1.000	.001	6	view →
LSCC	DFS	Quartile	III,IV	0.457	0.870	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IMPDH2–PDAC (OS)

Open the PDAC breakdown →